Skip to main content
. Author manuscript; available in PMC: 2015 Mar 24.
Published in final edited form as: Neuropharmacology. 2014 Mar 16;82:41–48. doi: 10.1016/j.neuropharm.2014.03.004

Fig. 6.

Fig. 6

Levels of kynurenic acid (KYNA), measured in the prelimbic cortex of rats, using in vivo microdialysis. Vehicle or PF (32 mg/kg; s.c.) was administered prior to KYN (KYN; 100 mg/kg; i.p.; see arrows). Repeated measures ANOVA and post hoc comparisons indicated that at 60–180 min, KYNA levels were significantly higher in rats given vehicle when compared to the KATII inhibitor (absolute KYNA levels [M ± SEM: baseline: vehicle + KYN: 2.17 ± 0.06 nM; PF + KYN: 1.77 ± 0.16 nM; average 60– 180 min: vehicle + KYN: 164.48 ± 10.09 nM; PF + KYN: 30.53 ± 1.64 nM).